Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How Patients Must Have Progressive Disease after 1st Line of Therapy to Enroll in ONC201 Trial. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.
Patients Must Have Progressive Disease after 1st Line of Therapy to Enroll in ONC201 Trial
